The FDA has approved sotorasib as the first treatment for adult patients with non–small cell lung cancer whose tumors harbor KRAS G12C mutations and who have received at least 1 prior systemic therapy. FDA The FDA has approved sotorasib (Lumakras) as the first treatment for adult patients ...